Understanding the Link Between Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Specific Safety Concerns

If you or a loved one has been taking Ozempic and now struggles with persistent nausea, vomiting, or feeling full after small meals, you may be facing gastroparesis. Decades of pharmacovigilance have long recognized that certain medications can slow gastric emptying, but the scale of GLP-1 receptor agonist use has brought new attention to this known risk. This page explains what the science currently shows about the connection, the FDA's position, and how to recognize the warning signs.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in higher doses, for chronic weight management. Its mechanism of action includes slowing gastric emptying, which contributes to glycemic control and satiety. However, this pharmacological effect can also lead to significant gastrointestinal adverse events, including gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction. Clinical presentation of gastroparesis typically includes nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis is confirmed through gastric emptying scintigraphy or breath tests, which measure the rate at which food leaves the stomach. Evidence from clinical trials and post-marketing surveillance indicates that gastrointestinal adverse reactions are common with Ozempic use. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Post-Marketing Evidence and Legal Implications for North Carolina Patients

Post-marketing adverse event reports from the FDA Adverse Event Reporting System (FAERS) further highlight the association between Ozempic and gastroparesis. Among the most frequently reported adverse events for Ozempic were nausea (8652 reports), vomiting (5578 reports), and impaired gastric emptying (2693 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). The term "impaired gastric emptying" is clinically synonymous with gastroparesis. Other related gastrointestinal symptoms included diarrhea (5274 reports), constipation (3859 reports), abdominal pain upper (2433 reports), abdominal pain (1946 reports), abdominal distension (1408 reports), and dyspepsia (1374 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC). These data suggest a mechanistic pathway linking Ozempic to gastroparesis: GLP-1 receptor agonists delay gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can become pathologically prolonged in susceptible individuals, leading to symptomatic gastroparesis. The adequacy of warnings regarding Ozempic and gastroparesis is a critical risk consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions, noting that they are most common during dose escalation and may lead to discontinuation. However, the label does not explicitly list gastroparesis as a separate warning or contraindication. Instead, it describes impaired gastric emptying as a pharmacological effect and lists gastrointestinal symptoms that overlap with gastroparesis. This may leave patients and healthcare providers unaware of the potential for severe, persistent gastroparesis requiring medical intervention. For affected patients, the timeline between exposure and documented harm can vary. Some individuals develop symptoms during dose escalation, while others may experience delayed onset after months of use. The FAERS data indicate that impaired gastric emptying is a frequently reported adverse event, suggesting that harm can occur at any point during treatment. For patients in North Carolina who have developed gastroparesis after using Ozempic, attorney-related considerations are important. Legal claims may focus on whether the manufacturer provided adequate warnings about the risk of gastroparesis. Evidence from clinical trials and post-marketing reports could support arguments that the risk was known or should have been known. Affected individuals should document their medical history, including the timing of Ozempic use, onset of symptoms, diagnostic tests confirming gastroparesis, and any treatments required. Consulting with a qualified attorney experienced in pharmaceutical litigation can help evaluate the strength of a potential claim. Legal considerations include statutes of limitations, which vary by state, and the need to demonstrate a causal link between Ozempic use and the development of gastroparesis. In summary, the evidence from clinical trials and FAERS data establishes a clear association between Ozempic use and gastroparesis. The pharmacological mechanism of delayed gastric emptying provides a plausible pathway for this adverse effect. While the prescribing information includes warnings about gastrointestinal reactions, it does not specifically highlight gastroparesis, raising questions about the adequacy of warnings. Patients in North Carolina who have experienced gastroparesis after using Ozempic should seek medical care and consider legal consultation to explore their options.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. In some individuals, this effect can become pathologically prolonged, leading to gastroparesis—a condition of delayed gastric emptying without obstruction. Clinical trials and post-marketing data from FAERS show a higher incidence of gastrointestinal adverse events, including impaired gastric emptying, among Ozempic users (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:OZEMPIC).

What legal options do North Carolina residents have if they developed gastroparesis from Ozempic?

North Carolina residents who developed gastroparesis after using Ozempic may pursue legal claims based on inadequate warnings. The prescribing information does not explicitly warn about gastroparesis, despite evidence from trials and FAERS. Affected individuals should document their medical history and consult a qualified attorney experienced in pharmaceutical litigation to evaluate their case, considering statutes of limitations and the need to prove causation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.